NCT03141086 - A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

August 30, 2018

Study Completion Date

September 12, 2018

Conditions

Circadian Rhythm Disorders

Interventions

DRUG

LML134

DRUG

Placebo

placebo

Trial Locations (8)

Novartis Investigative Site, New York

Novartis Investigative Site, Chevy Chase

Novartis Investigative Site, Atlanta

Novartis Investigative Site, Miami

Novartis Investigative Site, Oakland Park

Novartis Investigative Site, Cincinnati

Novartis Investigative Site, San Diego

Novartis Investigative Site, Los Angeles